Post-transplant lymphoproliferative diseases in Asian solid organ transplant recipients: Late onset and favorable response to treatment

Clinical Transplantation

Volumn 26, Issue 5, 2012, Pages 679-683

  Chan, Thomas S Y ^a   Hwang, Yu Yan ^a   Gill, Harinder ^a   Au, Wing Yan ^a   Leung, Anskar Y H ^a   Tse, Eric ^a   Chim, Chor Sang ^a   Loong, Florence ^a   Kwong, Yok Lam ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

Asia; Post transplant lymphoproliferative disorders

Indexed keywords

ANTINEOPLASTIC AGENT; LACTATE DEHYDROGENASE; RITUXIMAB;

ADULT; AGED; ARTICLE; ASIAN; BURKITT LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CLASSICAL HODGKIN LYMPHOMA; CLINICAL ARTICLE; EPSTEIN BARR VIRUS; FEMALE; GRAFT RECIPIENT; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LARGE CELL LYMPHOMA; LYMPHOMATOID PAPULOSIS; MALE; NK T CELL LYMPHOMA; ORGAN TRANSPLANTATION; PLASMA CELL LEUKEMIA; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; CHINA; DRUG THERAPY, COMBINATION; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOMA, B-CELL; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84867656829     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2011.01593.x     Document Type: Article

References (16)

1. DiNardo CD, Tsai DE. Treatment advances in posttransplant lymphoproliferative disease. Curr Opin Hematol 2010: 17: 368.
2. Dharnidharka VR, Tejani AH, Ho PL, Harmon WE. Post-transplant lymphoproliferative disorder in the United States: young Caucasian males are at highest risk. Am J Transplant 2002: 2: 993.
3. Swerdlow SH, Webber SA, Chadburn A, Ferry JA. Post-transplant lymphoproliferative disorders. In Swerdlow SH, Campo E, Harris NL et al. eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC, 2008: 343.
4. Evens AM, David KA, Helenowski I et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol 2010: 28: 1038.
5. Knight JS, Tsodikov A, Cibrik DM, Ross CW, Kaminski MS, Blayney DW. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center. J Clin Oncol 2009: 27: 3354.
6. Au WY, Lie AK, Kwong YL et al. Post-transplantation lymphoproliferative disease in Chinese: the Queen Mary Hospital experience in Hong Kong. Leuk Lymphoma 2002: 43: 1403.
7. Abe T, Ichimaru N, Kokado Y et al. Post-transplant lymphoproliferative disorder following renal transplantation: a single-center experience over 40years. Int J Urol 2010: 17: 48.
8. Au WY, Pang A, Chan EC, Chu KM, Shek TW, Kwong YL. Epstein-barr virus-related gastric adenocarcinoma: an early secondary cancer post hemopoietic stem cell transplantation. Gastroenterology 2005: 129: 2058.
9. Leblond V, Davi F, Charlotte F et al. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity?J Clin Oncol 1998: 16: 2052.
10. Nelson BP, Nalesnik MA, Bahler DW, Locker J, Fung JJ, Swerdlow SH. Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity?Am J Surg Pathol 2000: 24: 375.
11. Styczynski J, Einsele H, Gil L, Ljungman P. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl Infect Dis 2009: 11: 383.
12. Trappe R, Hinrichs C, Appel U et al. Treatment of PTLD with rituximab and CHOP reduces the risk of renal graft impairment after reduction of immunosuppression. Am J Transplant 2009: 9: 2331.
13. Kataoka K, Seo S, Sugawara Y et al. Post-transplant lymphoproliferative disorder after adult-to-adult living donor liver transplant: case series and review of literature. Leuk Lymphoma 2010: 51: 1494.
14. Coppoletta S, Tedone E, Galano B et al. Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011: 17: 901.
15. Gupta S, Fricker FJ, González-Peralta RP, Slayton WB, Schuler PM, Dharnidharka VR. Post-transplant lymphoproliferative disorder in children: recent outcomes and response to dual rituximab/low-dose chemotherapy combination. Pediatr Transplant 2010: 14: 896.
16. Worth A, Conyers R, Cohen J et al. Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation. Br J Haematol 2011: 155: 377.